Mainz Biomed NV
F:4TO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mainz Biomed NV
Cash & Cash Equivalents
Mainz Biomed NV
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mainz Biomed NV
NASDAQ:QUCY
|
Cash & Cash Equivalents
$889.1k
|
CAGR 3-Years
-63%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Cash & Cash Equivalents
€7.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Cash & Cash Equivalents
€481.7m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Cash & Cash Equivalents
€345.9m
|
CAGR 3-Years
33%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Immunic Inc
NASDAQ:IMUX
|
Cash & Cash Equivalents
$15.5m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-15%
|
|
|
Biotest AG
XETRA:BIO
|
Cash & Cash Equivalents
€41.8m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-10%
|
|
Mainz Biomed NV
Glance View
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 58 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
See Also
What is Mainz Biomed NV's Cash & Cash Equivalents?
Cash & Cash Equivalents
889.1k
USD
Based on the financial report for Dec 31, 2025, Mainz Biomed NV's Cash & Cash Equivalents amounts to 889.1k USD.
What is Mainz Biomed NV's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
49%
Over the last year, the Cash & Cash Equivalents growth was -86%. The average annual Cash & Cash Equivalents growth rates for Mainz Biomed NV have been -63% over the past three years , 49% over the past five years .
